Here's Why Pfizer Stock Is Looking Increasingly Attractive
You might already know the conventional wisdom about Pfizer (NYSE: PFE). It's quite gloomy. The company depends heavily on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid. Sales for both products are expected to decline significantly this year. Pfizer also faces patent expirations for several of its other best-selling drugs over the next few years. The stock, therefore, must be one to avoid.
But while I think the conventional wisdom is correct about the challenges that Pfizer faces, the conclusion about the stock is wrong. There's much more to the story for the big drugmaker. Here's why Pfizer stock is looking increasingly attractive.
Image source: Getty Images.
Source Fool.com
